Are All Adults with Neuroblastoma High Risk?
No, not all adults with neuroblastoma are automatically classified as high-risk, but the vast majority are. Risk classification depends on specific tumor characteristics including MYCN amplification status, stage, histology, and chromosomal aberrations—not age alone, though age ≥18 months is a significant risk factor 1.
Risk Classification Framework
According to the NCCN 2024 guidelines, neuroblastoma risk stratification is based on multiple factors 1:
High-Risk Criteria Include:
- Stage M disease in patients ≥18 months of age (regardless of other features)
- MYCN amplification (regardless of age or stage, except completely resected L1 disease)
- Stage L2 disease ≥18 months with unfavorable histology AND MYCN non-amplified
- Stage M disease 12 to <18 months with MYCN non-amplified PLUS any unfavorable features (unfavorable histology, diploid DNA, or segmental chromosomal aberrations)
Adults Can Have Non-High-Risk Disease If:
- L1 stage with MYCN non-amplified tumors are classified as low-risk
- L1 stage with MYCN amplified but completely resected are considered low-risk
- Certain intermediate-risk criteria may apply to adults with L2 disease meeting specific molecular profiles
Clinical Reality for Adult Patients
The general principles of high-risk therapy should be applied to older patients with high-risk disease, though these patients may require a more individualized approach based on comorbid conditions and tolerance of planned therapy 1. This acknowledges that while adults can theoretically have any risk category, most present with high-risk features.
Key Considerations:
- Clinical studies informing treatment guidelines predominantly included patients <5 years of age 1
- Adults with neuroblastoma have significantly worse outcomes than children, with 5-year survival rates of only 36.3% compared to 84.6% in infants 2
- Recent data show 64.6% of adolescents and adults present with high-risk disease 3
- Adults demonstrate less chemotherapy sensitivity and poorer outcomes compared to pediatric patients 3
Critical Pitfall to Avoid
Do not assume all adults are high-risk without proper molecular and staging evaluation. The risk classification system requires assessment of:
- MYCN amplification status (strongest independent prognostic factor) 1
- Segmental chromosomal aberrations (1p, 11q, 3p, 4p, 17q, 1q, 2p) 1
- INRG stage 1
- Histopathology (favorable vs unfavorable by INPC) 1
- Ploidy status 1
Each adult patient requires comprehensive molecular genetic testing to accurately assign risk category 1, as treatment intensity and prognosis differ dramatically between risk groups. The 5-year event-free survival for high-risk disease is approximately 51% 1, making accurate classification essential for appropriate treatment planning.